CPSE:NOVO BPharmaceuticals
Novo Nordisk Weighs Trial Win Against Growing GLP 1 Competition
Novo Nordisk (CPSE:NOVO B) released head to head ORION trial data showing oral semaglutide produced greater weight loss and better tolerability than Eli Lilly’s new orforglipron pill.
Eli Lilly has started the U.S. launch of its oral obesity pill under the brand name Foundayo, setting up direct competition in the oral GLP-1 market.
The European Medicines Agency approved more flexible cold chain rules for Wegovy, changing how the drug can be stored and handled.
In India, rapid growth of...